News and Announcements
Amogen Pioneer Newly Onboard with Actinogen Medical
- Published November 16, 2017 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
KEY TAKEAWAYS:
- Dr George Morstyn is joining Actinogen Medical as a non-executive director as of December 1, 2017.
- He brings extensive drug development experience to the role, with many new products receiving marketing approval.
- Dr Morstyn will work with Actinogen’s high calibre team to guide and optimise the development of XanamemTM.
As announced November 2, 2017, Actinogen Medical (ASX: ACW) proudly welcomes Dr George Morstyn, as a non-executive director on the board, beginning December 1, 2017. Dr Morstyn, a pioneer drug developer and former Amgen Inc. Executive, usher extensive drug development studies to the role with massive new products receiving approval of the market and launching products during his tenureship at Amgen.
Having worked in the 1980’s with the legendary Professor Don Metcalf “Order of Australia and Companion of the Order, regarded as the father of modern haematology”, at the Walter and Eliza Hall Institute. Dr Morstyn actively assisted establishing and pioneering the clinical development of the haemopoietic colony stimulating factors, the present champion in the standard treatment of patients suffering from cancer after chemotherapy. He worked as esteemed Senior Vice-President of Development and Chief Medical Officer at US biotech tower, Amgen (NASDAQ: AMGM, market capitalisation: US$128 billion), upon joining Amgen in its early formative years in 1991, when the company was a blossoming biotech. At Amgen, he was the key person for the development of medications, treatments across all therapeutic areas, including neuroscience as well.
Dr Morstyn will join with Actinogen’s highly renowned team to lead and optimise the development of XanamemTM for Alzheimer’s disease and various neurodegenerative conditions. Under his strong leadership in the medical arena, he dominated the marketing approval of many new products and subsequent successful commercial launches.
About Actinogen Medical Ltd (ASX: ACW)
Actinogen Medical Limited (ASX:ACW) is an Australian, publicly-listed early clinical-stage biotechnology company focused on the treatment of cognitive impairment and Alzheimer’s disease.
Company Updates
Dogs First to Reduce Risk: QBiotics’ Smarter Path to Oncology Markets
QBiotics took a compound derived from a north Queensland rainforest tree all the way to veterinary registration before pursuing human oncology to de-risk its human cancer programme. Interim CEO Ebru Davidson argues that sequence – now backed by early responses across several human cancers – is the company’s real asset. The story that pulled Wholesale […]
Built on discipline, not complexity: inside an ASX equities income strategy
Haydn Froggatt and Zac Brabin have decades of derivatives experience between them and access to almost any strategy in the market. They use two of the simplest structures available, and wrote 202 positions with them last year. Published by Fairway Capital Management. Based on an interview with co-founders Haydn Froggatt and Zac Brabin. Two traders, […]
BlackRock has named the next Economy. What this latest paper means for Private Market Investors.
BlackRock has put a name on something the smart money has been circling for two years. Its digital assets research team calls it the machine-native economy. The thesis fits in one line. AI is machine-native intelligence. Digital assets are machine-native money. Both are built on the same architecture, and they are converging into a single […]
Backed By Leading Investment Groups and Family Offices
